Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Stendörren in connection with a tap issue of SEK 300 million bonds
Mandate

Vinge has advised Stendörren in connection with a tap issue of SEK 300 million bonds

October 04, 2018 Banking and Finance

Vinge has advised Stendörren Fastigheter AB (publ) (“Stendörren”) in connection with a tap issue of SEK 300 million senior unsecured floating rate bonds. 

The bonds have a tenor of three years and a floating interest rate of three months Stibor plus 4.25 per cent. The proceeds from the subsequent bond issue will be issued for general corporate purposes. Swedbank has acted as Issuing Agent and financial advisor to Stendörren.

In accordance with the terms and conditions, the subsequent bonds are intended to be listed and admitted to trading on the corporate bond list at Nasdaq Stockholm shortly.

Vinge also advised Stendörren in connection with the company’s initial bond issue of SEK 350 million on 18 June 2018. A listing prospectus was approved by the Swedish Financial Supervisory Authority on 1 August 2018.

Vinges team consisted of Louise Brorsson Salomon, André Isacson and Fredric Reissmüller.

Related

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024

Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest

Vinge advises Triton Smaller Mid-Cap Fund I (“Triton”) in connection with the divestment of Norstat, a leading data collector for market research, to Nalka Invest.
April 12, 2024